Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial - Rovin BH; Barratt J; Heerspink HJL; Alpers CE; Bieler S; Chae DW; Diva UA; Floege J; Gesualdo L; Inrig JK; Kohan DE; Komers R; et al. (Lancet, 2023)